OBJECTIVES: In long-term HIV-infected patients, peripheral lipoatrophy (LA) and central lipohypertrophy (LH) appear to be related to the same insults (virus and antiretroviral drugs), but are likely to be associated with different fat depot physiologies. The objective of this study was to describe the natural history of lipodystrophy assessed using dual energy X-ray absorptiometry (DEXA) and computed tomography (CT) in a large HIV out-patients metabolic clinic. METHODS: An observational retrospective study was carried out including HIV-infected patients recruited at the Metabolic Clinic of Modena, Modena, Italy, who were assessed for lipodystrophy and had at least two anthropometric evaluations using DEXA for leg fat per cent mass and abdominal CT for visceral adipose tissue (VAT). Factors associated with leg fat per cent and VAT changes were analysed using multivariable generalized estimating equation (GEE) regression models. RESULTS: A total of 6789 DEXAs and 7566 CT scans were evaluated in the observation period. A total of 1840 patients were included; the mean age was 45.2 ± 7.2 (standard deviation) years, 621 (34%) were women, and the median HIV infection duration was 176 (interquartile range 121-232) years. According to the GEE multivariable regression analysis, leg fat per cent evaluated with DEXA appeared to increase over calendar years (ß = 0.92; P < 0.001); moreover, a progressive increase in VAT was observed in the cohort (ß = 5.69; P < 0.001). No association with antiretroviral drugs was found. CONCLUSIONS: In our study, neither LA nor LH appeared to be associated with antiretroviral drug exposure. We observed a progressive increase in LH in HIV-infected patients over calendar years. This anthropometric change, together with loss of appendicular lean mass, could describe a physiological aging process in HIV-infected patients.
OBJECTIVES: In long-term HIV-infectedpatients, peripheral lipoatrophy (LA) and central lipohypertrophy (LH) appear to be related to the same insults (virus and antiretroviral drugs), but are likely to be associated with different fat depot physiologies. The objective of this study was to describe the natural history of lipodystrophy assessed using dual energy X-ray absorptiometry (DEXA) and computed tomography (CT) in a large HIV out-patients metabolic clinic. METHODS: An observational retrospective study was carried out including HIV-infectedpatients recruited at the Metabolic Clinic of Modena, Modena, Italy, who were assessed for lipodystrophy and had at least two anthropometric evaluations using DEXA for leg fat per cent mass and abdominal CT for visceral adipose tissue (VAT). Factors associated with leg fat per cent and VAT changes were analysed using multivariable generalized estimating equation (GEE) regression models. RESULTS: A total of 6789 DEXAs and 7566 CT scans were evaluated in the observation period. A total of 1840 patients were included; the mean age was 45.2 ± 7.2 (standard deviation) years, 621 (34%) were women, and the median HIV infection duration was 176 (interquartile range 121-232) years. According to the GEE multivariable regression analysis, leg fat per cent evaluated with DEXA appeared to increase over calendar years (ß = 0.92; P < 0.001); moreover, a progressive increase in VAT was observed in the cohort (ß = 5.69; P < 0.001). No association with antiretroviral drugs was found. CONCLUSIONS: In our study, neither LA nor LH appeared to be associated with antiretroviral drug exposure. We observed a progressive increase in LH in HIV-infectedpatients over calendar years. This anthropometric change, together with loss of appendicular lean mass, could describe a physiological aging process in HIV-infectedpatients.
Authors: Marisela Noorhasan; Daniel R Drozd; Carl Grunfeld; Joseph O Merrill; Greer A Burkholder; Michael J Mugavero; James H Willig; Amanda L Willig; Karen L Cropsey; Kenneth H Mayer; Aaron Blashill; Matthew Mimiaga; Mary E McCaul; Heidi Hutton; Geetanjali Chander; William C Mathews; Sonia Napravnik; Joseph J Eron; Katerina Christopoulos; Rob J Fredericksen; Robin M Nance; Joseph Chris Delaney; Paul K Crane; Michael S Saag; Mari M Kitahata; Heidi M Crane Journal: AIDS Res Hum Retroviruses Date: 2017-02-16 Impact factor: 2.205
Authors: Samuel S Bailin; Curtis L Gabriel; Run Fan; Fei Ye; Sangeeta Nair; James G Terry; John J Carr; Heidi Silver; Celestine N Wanjalla; Mona Mashayekhi; Morgan Lima; Beverly Woodward; LaToya Hannah; Hubaida Fuseini; Jane F Ferguson; Jonathan A Kropski; John R Koethe Journal: J Acquir Immune Defic Syndr Date: 2022-06-01 Impact factor: 3.771
Authors: Jordan E Lake; Takara L Stanley; Caroline M Apovian; Shalendar Bhasin; Todd T Brown; Jaqueline Capeau; Judith S Currier; Michael P Dube; Julian Falutz; Steven K Grinspoon; Giovanni Guaraldi; Esteban Martinez; Grace A McComsey; Fred R Sattler; Kristine M Erlandson Journal: Clin Infect Dis Date: 2017-05-15 Impact factor: 9.079
Authors: Catherine M Jankowski; Samantha Mawhinney; Melissa P Wilson; Thomas B Campbell; Wendy M Kohrt; Robert S Schwartz; Todd T Brown; Kristine M Erlandson Journal: J Acquir Immune Defic Syndr Date: 2020-11-01 Impact factor: 3.771
Authors: Charlotte M Verolet; Cécile Delhumeau-Cartier; Marlène Sartori; Simona Toma; Sophie Zawadynski; Minerva Becker; Enos Bernasconi; Laurence Toutous Trellu; Alexandra Calmy Journal: AIDS Res Ther Date: 2015-06-20 Impact factor: 2.250
Authors: André P Dos Santos; Anderson M Navarro; Andiara Schwingel; Thiago C Alves; Pedro P Abdalla; Ana Claudia R Venturini; Rodrigo C de Santana; Dalmo R L Machado Journal: BMC Public Health Date: 2018-06-27 Impact factor: 3.295